Genomic Tests Firm Exagen Buying Cypress’ Dx Biz | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exagen Diagnostics has agreed to buy the diagnostics business of Cypress Bioscience for up to $8 million in upfront and milestone payments.

Under the terms of the agreement announced Friday after the close of the market, Exagen will pay $4 million upfront, split into two separate payments 24 months apart, Cypress said in a statement. Exagen will also make milestone payments totaling up to $4 million and pay a 10 percent royalty to Cypress on defined product sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.